drugset / Trial / NCT01094496

A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)

NCT01094496

Phase 2 Terminated 3 enrolled Celldex Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

The major purpose of this study is to examine the anti-tumor activity of the CDX-1307 vaccine regimen when it is given before and after bladder cancer surgery. The study will also provide information about the safety of the vaccine regimen when given in combination with chemotherapy, and how it affects the immune systems.

Timeline

Start
2010-04
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject CDX-1307 Vaccine
Subject Hiltonol Other / unclassified
Subject Resiquimod Small molecule
Subject sargramostim Protein / enzyme biologic